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Background
Patients are living longer with incurable cancer [1] such
that in many cases, cancer is likened to a chronic disease
[2–4]. This development has wide-ranging implications
for both patients and wider society, with increased lon-
gevity comes increased morbidity and associated
socio-economic burden [5, 6]. Primary cost drivers for
patients with advanced cancer are hospitalisation, GP
and domiciliary visits [7]. Rehabilitation has been advo-
cated as one such way of optimising the function and
quality of life in this group of patients [8]; however, the
optimal components of a rehabilitation model for pa-
tients with incurable cancer remain to be elucidated.
In the past, there was a therapeutic nihilism that func-
tional decline, cachexia and psychological distress were in-
evitable consequences of cancer [9, 10]. This is no longer
the case and differs markedly from the modern palliative
care approach, where advancements in symptom manage-
ment, embraced in holistic care, have made dramatic im-
provements in the care of patients over the past 30 years.
However, this progress has been slow to incorporate re-
habilitation; indeed optimising physical function and nu-
tritional status has largely been ignored [11]. Patients,
their families and clinicians realise that optimising quality
of life is a fundamental component of good cancer care
and that maintaining physical function and nutrition is as
important as good symptom control [12]. Although clear
guidance exists on symptom control, programmes which
optimise physical and nutritional function have been the
exception rather than the norm.
The concept of rehabilitation is widely established for
the management of chronic diseases such as chronic re-
spiratory disease [13]; yet in palliative care, the concept
of rehabilitation remains largely elusive. Rehabilitation in
the context of patients with incurable cancer aims to im-
prove function where there is a capacity to do so, to
maintain function where the effects of the illness or its
treatment threaten to cause decline and to ease the tran-
sition toward functional decline where deterioration is
inevitable [14].
In 2015, Hospice UK published a report advocating
that “rehabilitative palliative care is an essential compo-
nent of palliative care” [8]. This comprehensive report
argued that rehabilitation should focus on function, be
person-centred and enable patients to live fully by main-
taining or adapting their functional independence while
supporting self-management. Guidance was also offered
on how rehabilitation should be implemented in the UK,
including adopting and embedding a culture of rehabili-
tative palliative care. However, there is limited robust
evidence on which to base this approach. A recent sys-
tematic review examining rehabilitation in advanced
cancer identified only a small number of studies in this
area [4]. Evidence suggests that rehabilitation may be
feasible for patients with advanced cancer, but key com-
ponents are not clear and no firm recommendations
could be given. A further review has highlighted the lack
of studies examining combined exercise and nutrition
interventions for patients with advanced cancer [11].
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While there is evidence of the benefits of rehabilita-
tion in non-malignant conditions, such as chronic re-
spiratory disease [13], extrapolating these models to
incurable cancer care needs evaluation. The majority
of work to date in patients with incurable cancer has
focused on exercise as a single intervention [15]. Al-
though exercise is important, it has been argued that
any rehabilitation programme in incurable cancer
should also focus on nutritional aspects [11]. This
would seem logical as approximately 20% of cancer
deaths are directly attributable to cancer cachexia, and
cachexia is highly prevalent in patients with advanced
cancer [9, 16]. Cachexia is the multifactorial syndrome,
defined by ongoing loss of skeletal muscle mass (with
or without loss of fat mass) that cannot be fully re-
versed by conventional nutritional support, causing
progressive functional impairment [17]. Optimising
nutrition is fundamental to facilitate post-prandial an-
abolism, which is key to maintaining muscle and thus
physical function [18]. There is a persuasive argument
that exercise and nutrition should be considered as
cornerstones of rehabilitation programmes in patients
with incurable cancer [19]. However, this remains to
be demonstrated in clinical practice.
Previous studies have demonstrated the detrimental
effect of deteriorating physical function on survival
[20]. It therefore follows that optimising physical func-
tion may have survival benefits. At the very least, it
may enable patients to remain independent for longer
periods. Previous work by our group has examined an
exercise and nutrition-based intervention in oncology
outpatients with lung and pancreatic cancer undergo-
ing chemotherapy and demonstrated that such an
intervention was feasible and had beneficial effects on
physical function and weight [21]. A recent rando-
mised control trial has shown good adherence to an
exercise and nutritional intervention in palliative lung
and gastrointestinal cancer patients, with beneficial ef-
fects on symptoms of nausea and vomiting and protein
intake [22].
These findings are encouraging; however, the potential
benefits of an exercise and nutrition-based rehabilitation
programme in a general population of patients with incur-
able cancer remain unclear. The ENeRgy trial aims to de-
termine whether an exercise and nutritional rehabilitation
programme is feasible in a hospice outpatient setting for
patients with incurable cancer. It aims to also examine
changes in physical function, nutritional status and quality
of life in these patients. Effects on partner-carer quality of
life as well as healthcare resource utilisation will also be
examined. A companion qualitative study, ‘ENeRgy-Q’, will
be undertaken to explore acceptability, compliance and
the psychosocial impact of this rehabilitation programme
for patients with incurable cancer in the hospice setting.
Methods
Design
This is a randomised, unblinded feasibility trial of an
Exercise and Nutrition-based Rehabilitation programme
(ENeRgy) versus standard care in patients with incurable
cancer. Full ethical approval has been given (17/WS/
0226), and the trial will be conducted according to
principles of Good Clinical Practice and the Declaration
of Helsinki.
Population
Eligible patients will meet the following key criteria: ≥ 18
years of age, Karnofsky Performance Status (KPS) ≥ 60,
diagnosis of incurable cancer (defined as metastatic or
locally advanced cancer not amenable to curative
treatment), not undergoing anti-cancer therapy (hormonal
treatment or bisphosphonates permitted) with a prognosis
greater than 3months. Eligible patients are community-
dwelling and have the capacity to consent and complete
trial-based assessments. Participants will be identified and
referred to the trial from one of two hospice community
palliative care teams or from the regional oncology ser-
vice. Patients undergoing anti-cancer therapy (excluding
hormone or bisphosphonate treatments), using enteral
nutrition, unable to swallow or co-enrolled in drug trials
are excluded. Figure 1 details the trial schematic. The con-
sent process will be opt in, and written informed consent
will be obtained by the trial research nurse or doctor.
After baseline assessments (which occur over 7 days; week
0), patients will be randomised (1:1 stratified by baseline
KPS 60–80%, 90–100%) to receive either an 8-week exer-
cise and nutrition-based rehabilitation programme (treat-
ment arm) or standard care (control arm). Patients
randomised to the control arm will be offered the study
intervention after trial completion.
The trial is being conducted in a single centre (a hos-
pice) serving a geographically defined region in the UK
with a population of approximately one million.
Trial-related assessments will take place at an outpatient
clinic at this hospice. Management of the trial will be
overseen by a Trial Management Group (TMG). Patient
and public involvement (PPI) for the trial has been pro-
vided by Marie Curie’s Expert Voices group, as well as an
ex-carer of a patient with cancer. PPI input has been
highly valued, ranging from design of trial documents to
regular presence at TMG meetings.
Interventions
Treatment arm
The treatment arm is an exercise and nutrition-based re-
habilitation programme. Patients allocated to this arm
will have an interview with the trial physiotherapist and
dietitian at week 1. They will then be given an individua-
lised exercise and nutrition-based rehabilitation
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programme following this assessment. Key components
of this include the following:
Exercise A home-based exercise programme is supported
by a booklet. This will consist of aerobic and resistance ex-
ercise in divided sessions of the patient’s choosing. The
aerobic component comprises a total of 60min of physical
activity over the course of each week at moderate inten-
sity, i.e. feeling warm and getting slightly out of breath
(able to talk), equivalent to an intensity of 3–4 rating of
perceived exertion on a modified Borg scale [23]. Walking
will be recommended as the main type of physical activity
although cycling or more vocational forms of activity, e.g.
heavy housework and gardening, can be used as long as
they provoke the desired level of exertion. The resistance
component involves major muscle groups in the upper
and lower body (e.g. half squats, standing press-ups,
shoulder press) and will be recommended three times per
week. Patient diaries will record the amount of resistance
and aerobic exercise taken daily and any difficulties with
particular exercises.
Nutrition The main goal of the nutritional intervention
is to promote energy balance and to ensure optimal nu-
tritional intake. The nutritional component consists of
individual dietary counselling to enhance overall dietary
intake [19, 21] and oral nutritional supplements (ONS).
Individual dietary counselling will continue weekly
throughout the trial by the trial dietitian. Dietary advice
will be tailored and take into account any specific re-
quirements, e.g. ethnic background. Patients will be
instructed to take two ONS per day. One ONS portion
(220 mL) contains 1 g of eicosapentaenoic acid (EPA),
and the caloric distribution is relevant for cancer
patients experiencing unintended weight loss. Patients
not able to tolerate the ONS due to personal preference
will be offered an alternative ONS plus capsules contain-
ing 2 g EPA. Patient information leaflets will detail varied
ways to take the ONS to improve compliance, and diar-
ies will record the numbers of ONS taken daily.
At weekly review appointments, patient diaries will be
reviewed by the research nurse for healthcare-related re-
source use; adverse events will also be screened for and
logged. The trial dietitian will review the patients’ dietary
intake and compliance with the ONS, and the trial physio-
therapist will review exercise progress, offer goal setting
and prompt any changes needed to maintain compliance.
Control arm
Patients randomised to the control arm will continue to
receive standard care from their GP and community
palliative care team on an as required basis according
to individual patient need. This care may also include
referral to other members of the community-allied
healthcare professional MDT team if required (for ex-
ample counsellors, occupational therapist or social
workers). The control group will be phoned at weekly
intervals by the research nurse to ascertain levels of
healthcare-related utility and adverse events. In the
control group, patients will also have diaries to record
any (non-trial) nutritional supplements they are taking
as well as the amount and type of exercise undertaken
each week. This will help gauge any degree of contam-
ination in the control group.
Patients in the control arm will be offered the op-
portunity to undertake the rehabilitation programme
at the end of their involvement in the trial if they
wish to do so.
Fig. 1 Trial schematic
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Outcomes
The primary endpoint is to evaluate the feasibility of de-
livering the exercise and nutritional rehabilitation
programme in a hospice outpatient context. This will be
assessed by measuring compliance with the rehabilita-
tion programme (numbers of exercises and nutritional
supplements versus those advised). Compliance with
trial procedures will also be measured, including com-
pletion of diaries and questionnaires, percentage with-
drawal, completion of physical tests and completeness of
physical activity monitor data.
Secondary endpoints will examine the feasibility of
recruitment and retention, evidence of contamination in
the control group and change in physical function and
nutritional status. Quality of life measures for patients (±
partner-carers) and impact on patient healthcare-related
resource use in terms of cost between sectors of the NHS,
social services, third sector, participant expenses and carer
costs will also be examined. All endpoints will be assessed
at baseline (pre-randomisation—week 0) and at trial end-
point (week 9). Table 1 details a summary of trial-related
assessments and time points.
Statistical considerations
The primary endpoint of this study is to assess the feasi-
bility of the treatment (an exercise and nutrition-based
rehabilitation programme). As such, a formal sample size
calculation has not been performed. We plan to recruit
over a 13-month period and expect to be able to obtain
at least 40 participants over that timeframe.
Intention-to-treat analysis will be performed.
The primary outcome measures will be presented de-
scriptively using appropriate summary statistics with
corresponding 95% confidence intervals. Demographic
statistics and exploratory outcome measures shall also
be presented using appropriate summary split by treat-
ment group. Continuous outcome measures, for ex-
ample, change in daily step count and change in weight,
will be compared between treatment arms using two
sample t tests or non-parametric equivalent as appropri-
ate. Rates of compliance will be reported along with
completion rates for all other outcome measures. This
feasibility trial is not powered to explore efficacy, but
these estimates of variability will be used to inform the
sample size and inform our choice of primary endpoint
for the definitive trial. There are no plans to perform an
interim analysis while recruitment is ongoing or before
follow-up is completed. Estimation of economic parame-
ters will rely on questionnaires designed to measure
health-related utility, healthcare-related resource use and
costs, administered at baseline and follow-up assessment
time points. Unit costs will be assigned using standard
national costing sources where available or through con-
sultation with relevant service business managers. Costs
Table 1 Trial-related assessments and time points (both arms)
Baseline measures (week 0) Midpoint (week 5) Endpoint (week 9)
Demographics • Gender, primary tumour site and tumour status;
metastatic sites; current hormone/bisphosphonate
or steroid treatment
• N/A • N/A
Physical
measures
• Height
• Weight
• Weight • Weight
Quality of life
(QOL) measures
• Patient QOL (EORTC QLQ-C15-PAL questionnaire) [24]
• Partner-Carer QOLa (Caregiver Quality of Life Index-Cancer
Questionnaire (CQOLC)) [25]
• EQ-5D-5L & EQ-VAS [26] questionnaires
• Patient QOL (EORTC QLQ-C15-PAL)
• Partner-Carer QOLa
(CQOLC)
• EQ-5D-5L & EQ-VAS
questionnaires
• Patient QOL (EORTC QLQ-C15-PAL)
• Partner-Carer QOLa (CQOLC)
• EQ-5D-5L & EQ-VAS
questionnaires
Functional
measures
• Karnofsky Performance Status (KPS) [27]
• Life Space Assessment questionnaire (LSA) [28]
• Two-minute walk test [29]
• Timed up and go test [30]
• KPS
• LSA
• Two-minute walk test
• Timed up and go test
• KPS
• LSA
• Two-minute walk test
• Timed up and go test
Socio-economic
measures
• Socio-economic background (employment status, benefits
received, carer responsibilities, current use of social services)
• Healthcare utilisation and expenses questionnaire
• Healthcare utilisation and
expenses questionnaire
• Healthcare utilisation and
expenses questionnaire
Physical activity
meter (PAM)
• PAM worn continuously for 7 daysb
(data retrieved at week 1)
• Mean daily step count
• Hours asleep/ restless/ awake per night
(PAM worn only at
baseline and end point)
• PAM worn continuously for 7
daysb (data retrieved at week 10)
• Mean daily step count
• Hours asleep/restless/awake
per night
Nutritional
measures
• Abridged Patient-Generated Subjective Global
Assessment (aPG-SGA) [31]
• Ten-point verbal analogue scale (AveS) [32]
• aPG-SGA
• AveS
• aPG-SGA
• AveS
a‘Partner-carer’ is a partner with whom the patient is married, cohabiting or non-cohabiting, and the patient also describes as their carer
bPAM data for weekend days may be excluded to reduce potential variation
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will be summarised from the perspectives of (a) the
NHS, (b) the charitable and 3rd sector, (c) the patient
and their carers and (d) wider society. A
proof-of-concept health economic model will be con-
structed taking the form of a probabilistic decision
model that simulates the passage of patients through the
clinical pathway defined by discrete health states, allow-
ing estimation of costs, quality of life and survival. The
model will be parameterised using data from the feasibil-
ity trial where possible, supplemented by data from the
published literature. Cost-effectiveness will be presented
as the incremental cost-effectiveness ratio (ICER),
expressed as cost per QALY gained.
A computer-generated randomisation schedule will be
produced using a random block size to allocate patients
at random in a 1:1 ratio to either the treatment arm
(personalised exercise and nutrition-based rehabilitation
programme) or control arm (standard care) via sealed
envelopes. The randomisation will be stratified by per-
formance status due to its influence on prognosis to en-
sure that patients with differing prognoses are equally
distributed between arms (KPS of 60–80% versus KPS
90–100%). Randomisation will occur at baseline (week
0) but will be blinded to patients until week 1 when it
will be revealed by the research nurse so as not to influ-
ence baseline activity levels in either group during base-
line assessments.
Paper case report forms (pCRF) will be used, and data
will be entered directly into an electronic data base. A
10% check will be undertaken on all inputted data to en-
sure validity. Patients will be identified by a unique trial
identification number, and patient identifiable data will
be kept locked securely within the hospice. Standard op-
erating procedures (SOPs) issued by the trial sponsor
(ACCORD/NHS Lothian) will be adhered to for example
reporting deviations from the protocol or serious ad-
verse events (SAEs).
Discussion
One of the fundamental arguments supporting rehabili-
tation is the changing face of cancer. Although initially
regarded as a terminal disease, cancer is morphing into a
chronic condition which in combination with its increas-
ing incidence will mean that more patients are ‘living
with’ rather than ‘dying from’ their cancer. Combined
with an ageing population, this means that the popula-
tion who would fit under the umbrella of palliative care
is likely to rise considerably over the coming decades. It
is important that in view of this potential increase in pa-
tient numbers, the overall condition of patients is opti-
mised through maximisation of physical function and
nutritional status.
The ENeRgy trial is a key step in defining, developing
and assessing the feasibility of an exercise and
nutrition-based rehabilitation programme in this patient
cohort. We will use the trial to test the mechanism of
healthcare resource use data capture with a view to iden-
tifying key possible drivers of cost differences. The re-
sults of this trial and subsequent studies have the
potential to significantly impact and influence the ap-
proach to rehabilitation for patients with incurable can-
cer in the future.
Trial status
The description of the trial is in keeping with the ap-
proved version of the trial protocol (version 3, date 15
April 2018). The trial has been open to recruitment from
30 January 2018, and recruitment is expected to last 13
months, ending on 28 February 2019.
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